INTRODUCTION
The radioimmunoassay (RIA)' studies of Abe et al. (1) (2) (3) appeared to establish that the 22 polypeptide, human 3-melanocyte-stimulating hormone (h,fMSH) (4) was the principal pigmentary hormone in man. However, Scott and Lowry (5) and Bloomfield et al. (6) reinvestigated the nature of immunoreactive (IR) h,JMSH and were unable to demonstrate a molecule of this size in extracts of normal human pituitary or in unextracted plasma from two patients with pituitary tumors and progressive hyperpigmentation after total bilateral adrenalectomy for Cushing's disease (Nelson's syndrome). Instead, they found that most IR-,fMSH corresponded in size to ,8-lipotropin (,BLPH), a 91 amino acid molecule whose 37-58 sequence is identical with that of h,/MSH (7) with lesser amounts corresponding in size to yLPH ([ ,3LPH) in pituitary extracts (5) but not in plasma (6) . Therefore, they questioned the existence of h,3MSH and presented evidence that it was an artifact produced by enzymic degradation of ,JLPH during the weak acid extraction originally employed for isolating h,8MSH from human pituitaries (8) . These observations have been confirmed by ourselves and others (9) (10) (11) (12) . However, although our preliminary studies (9) (10) (11) and the published work of others (12) suggested that ,3LPH was the smallest IR-LPH in human plasma and tissue, we more recently found evidence that yLPH concentrations might equal or exceed those of' LPH in many human plasma and tissue specimens. The potential importance of this distinction is that the 61-91 sequence of ,BLPH contains the endogenous opiatelike peptides, methionine-enkephalin (13) and the endorphins (14, 15) . Thus, if a major circulating LPH were 'yLPH, the opiate peptides contained in the remaining 59-91 sequence of the 8LPH precursor molecule might also circulate in plasma and possibly exert their effects on a variety of' target tissues.
In this study, the apparent molecular sizes of IR-LPH in unextracted human plasma and extracts of plasma and tissues were characterized by gel filtration and compared with those of highly purified reference h,3LPH and hyLPH. METHODS 
Preparation of samples
Pituitary tissue. A single normal whole human pituitary gland obtained at autopsy and fresh-frozen whole human pituitary glands provided by the National Pituitary Agency were stored at -700C until they were extracted. The f'rozen glands were homogenized in ice-cold glacial acetic acid (19 ml/g tissue) by three 15-s bursts in a Waring blender (Waring Products Div., Dynamics Corp. of America, New Hartford, Conn.), cooling the contents of the blender cup in an ice bath between bursts. The homogenate was centrifuged at 6,000 g for 20 min at 4°C, and the supernate was stored at -700C.
Pituitary tumor culture medium. A pituitary tumor causing Nelson's syndrome (progressive hyperpigmentation after bilateral total adrenalectomy as treatment for Cushing's disease) was obtained at surgery. The tumor cells were dispersed and cultured at 37°C in Dulbecco's modified Eagle's minimal essential medium (North American Biologicals, Inc., Miami, Fla.) containing 15% horse serum and 2.5% fetal calf serum (Grand Island Biological Co., Grand Island, N. Y.) under a 12% CO2 atmosphere. After 2 wk of culture, during which the medium was replaced every [2] [3] [4] days, the medium was aspirated, the adherent cells were washed several times with 10-20 ml of fresh medium, and 25 ml of fresh medium was added. After an additional 3 days of' incubation, the medium was aspirated, centrifuged at 6,000 g for 15 min at 4°C, and the supernate was carefully decanted and stored at -70°C.
Nonpituitary tumor tissue. Tumor tissues (a medullary carcinoma of the thyroid, a pancreatic islet cell carcinoma, and an epithelial thymoma) causing the ectopic ACTH syndrome were obtained from three patients at surgery and homogenized immediately or after storage at -70°C in icecold deionized, glass-distilled water (9.0 ml/g tissue); the supernate was prepared and stored as described above.
Plasma. Lightly heparinized blood was obtained from normal subjects, one patient with untreated primary adrenal insufficiency (Addison's disease), four patients with Nelson's syndrome, and three patients with ectopic ACTH syndrome. Endogenous IR-LPH was suppressed in normal subjects by oral administration of dexamethasone, 2 mg at bedtime and 2 mg the next morning; blood was obtained 2 h later. All blood was chilled immediately and centrifuged at 2,000 g for 15 min at 40C. Plasma was aspirated, transferred to another polypropylene tube, and centrifuged at 6,000 g for 10 min at 40C (16) . The plasma was carefully decanted and stored at -70°C.
Gel exclusion chromatography
All chromatography was performed at 4°C. Five different columns were prepared for the purposes of this study.
Large G-50 column. This column was used for initial analyses of plasma and tissue extracts. A 5 x 90-cm column was packed with Sephadex G-50 fine resin (Pharmacia Fine Chemicals, Div. of Pharmacia Inc., Piscataway, N. J.), e(quilibrated, and developed with 0.1 M ammonium acetate that was adjusted to pH 7.4 with 14.8 M ammonium hydroxide. Samples and calibration standards were eluted by descendinig flow (50 cm hydrostatic pressure, 3.8 ml/cm2 per h) and 16.8-ml fractions were collected. Calibration standards were dissolved in 10 ml of column buffer, and the sample volume was 10 ml or was diluted 10 ml with the column buffer, except for 34.6 and 36.2 ml of two tumor extracts that were applied.
Small G-50 column. This column was used f'or studies of extraction efficiency. A 1.6 x 88-em column was prepared in the manner described above. A 2-ml sample or calibration standard was eluted by descending flow (23 cm hydrostatic pressure, 4.5 ml/cm2 per h), and 1.6-ml fractions were collected.
G-75 Column. This column was used to characterize IR-LPH in an extract of pooled human pituitaries. A 5 x 90-cm column of' Sephadex G-75 (Pharmacia Fine Chemicals, Div. of Pharmacia Inc.) was prepared as described above. 20-ml samples or standards were eluted by deseendinig flow (50 cm hydrostatic pressure, 3.8 ml/cm2 per h), and 17.0-ml fractions were collected.
G-100 Column. This column was used to characterize IR-LPH in plasma from a patient with Nelson's syndrome. A 5 x 90-cm column of Sephadex G-100 (Pharmacia Fine Chemicals, Div. of Pharmacia Inc.) was prepared as described above. 10 ml of samples or standards was eluted by gravity flow (35 cm hydrostatic pressure, 2.7 ml/cm2 per h), and 17.0-ml fractions were collected.
CL-6Blguanidine-HC1 column. This column was used to characterize IR-LPH under denaturing coniditions. A 1.6 x 90-cm column was packed with cross-linked agarose resin (Sepharose CL-6B, Pharmacia Fine Chemicals, Div. of Pharmacia Inc.), equilibrated, and developed with a 0.1-M phosphate buffer, pH 7.0, made 6 M with guanidine-HCI (Gdn-HCI) (Ultra-pure, Schwarz/Mann Div., Bectin, Dickinson, and Co., Orangeburg, N. Y.) (17) . A 1-ml sample or standard was eluted by ascending flow (15 cm hydrostatic pressure, 1.33 ml/cm2 per h) and 19-drop fractions were collected in individually preweighed polypropylene tubes containing 0.5-ml RIA standard diluent with twice the usual protein concentration to prevent the adsorption of peptides to the plastic; the actual fraction size was determined by weight (17) . Each sample or standard was preincubated in a 6-M Gdn-HCl phosphate buffer f'or 18 
LPH radioimmunoassayt
Procedure. The RIA fur LPH was performed (16, 23) using an antiserum, G-106, wvhose characteristics have been described (23) . This antiserum was raised2 in a guinea pig injected subcutaneously with commercial porcine ACTH (Corticotrophin-Zinc, 50 U/ml, Organon Inc., West Orange, N. J.) which is heavily contaminated with porcine MSH, a molecule which shares the 47-58 amino acid se(uence of human BLPH and yLPH (16, 23) . Pturified hlyLPH (Dr. Lowvry) and hJ3LPH (Dr. Li and Dr. Lowry) generated displacement curves parallel to synthetic (37-58)hLPH standard (Ciba-Geigy Ltd.) and, on a molar basis, were 82 and 58% as effective, respectively, as the synthetic LPH fragment in competing with I251-(37-58)hLPH for antibody-binding sites (23) ; all results are expressed as weight e(quivalents of synthetic (37-58)hLPH standard. The antibody demonstrated <0.1% cross-reactivity with either synthetic a-MSH or hACTH (both from Ciba-Geigy Ltd.). Thus, this is a (47-58)hLPH RIA. Two studies were performed with an antiserum, R-3, raised in a rabbit injected intradermally with synthetic (37-58)hLPH covalently bound to bovine serum albumin, which demonstrated similar specificity (23 No IR-LPH the size of h,3MSH was detected.
Thus, two components, 13-and yLPH, accounted for essentially all of the IR-LPH in these extracts, and concentrations of yLPH appeared to be equal to or greater than those of ,3LPH.
Plasma IR-LPH in patients with pituitary LPH hypersecretion. Unextracted plasma from four patients with Nelson's syndrome was subjected to Sephadex G-50 gel filtration ( Fig. 2A-D) . In each, the smallest IR-LPH peak had the apparent molecular size (Kd = 0.34 -0.40) of yLPH. In each, the concentration of 'yLPH exceeded that of BLPH, which was virtually absent in two of them (Fig. 2C, D) . In three of the plasmas, IR-LPH was observed in the column void volume, representing a major component ofone ofthem (Fig. 2B) .
The IR-LPH secreted by pituitary tumors causing Nelson's syndrome were also characterized by culturing tumor cells and examining the medium in which they were cultured. Three major IR-LPH peaks were observed (Fig. 2E) , one in the void volume, one (Kd = 0.20) similar in molecular size to 83LPH, and one (Kd = 0.40) that appeared to be yLPH.
Because these data were all concerned with IR-LPH secreted by pituitary tumors, unextracted plasma from a patient with a normal pituitary gland and LPH hypersecretion due to Addison's disease was examined. The major peak of IR-LPH (Kd = 0.38) appeared to be yLPH; only small amounts eluted before this single major peak (Fig. 2F) .
No IR-LPH the size of h/BMSH was observed in any of these specimens. Thus, 18-and yLPH accounted for most of IR-LPH in most plasma specimens, and yLPH concentrations equaled or exceeded those of /3LPH in each; variable amounts of still larger IR-LPH were also observed.
IR-LPH in nonpituitary tumor extracts. Because IR-LPH secretion is almost invariably associated (2) with that of ACTH by tumors causing the ectopic ACTH syndrome, we examined the IR-LPH in extracts of tumors from such patients. In each, the major IR-LPH peak (Kd = 0.36 -0.39) coeluted with purified hyLPH (Fig.  3A-C) and, in one of the tumor extracts (Fig. 3C) 
., r.
-. E-. Fig. 1; two extracts (A,B) were assayed vith R-3 antiserum; consecutive (D,E) or alternate (A-C,F) fractions were assayed and plotted.
h,3MSH-sized components were sometimes present, albeit in relatively small amounts.
Plasma IR-LPH in patients with nonpituitary tumors. In unextracted plasma from each of three patients with ectopic ACTH syndrome, IR-LPH was found in fractions from the void volume through the elution volume of yLPH (Fig. 3D-F) . Although high molecular weight LPH predominated, significant peaks of yLPH-sized IR-LPH were also observed in two plasmas (Fig. 3D, E (5, 6) .
Plasma IR-LPH under denaturing conditions. The three major IR-LPH peaks from Sephadex G-50 filtration of plasma from a patient with Nelson's syndrome (Fig. 2B , Kd = 0.08-0.05, 0.13-0.21, and 0.30-0.42, respectively) were analyzed by gel filtration in 6 M Gdn-HCl. Of the two smaller peaks, the larger peak (Fig. 4D ) appeared to be J3LPH and the smaller peak, yLPH (Fig. 4E) . In contrast, the IR-LPH that had eluted in the G-50 column void volume now appeared to consist mostly of -yLPH (Fig. 4C) (Fig. 2B) . (E) The third plasma IR-LPH peak (Kd = 0.30-0.42) (Fig. 2B) These results demonstrated that the silicic acid extractioin procedure was efficient for 8-and yLPH and did not artifactually prodtuce y-from inLPH.
IR-LPH in normal plasma. Because LPH RIA sensitivity was such that small concentrations of IR-LPH peptides could easily have escaped detection in G-50 fractions of unextracted plasma, 250 ml of plasma was obtained from two normal subjects at about 8:00 a.m., extracted wvith silicic acid using the usual proportion of silicic acid:plasma volume (23), lyophilized, reconstituted in column buffer, and applied to the large G-50 coltumn. In both, three peaks of IR-LPH were observed; one in the void volume, a second coeluting (K,d = 0.19) with h,8LPH, and a third predominant peak coeluting (K, = 0.37) with h-yLPH (Fig. 5) . The void volume competitive binding curves were again less steep than that of the standard. However, neither sample contained >0.06% of the void volume IR-LPH in an equal amount of plasma from one patient with Nelson's syndrome (Fig. 2B) .
These data excluded the presence of eveni very small quantities of IR-LPH other than ,-, y-and void volume IR-LPH in normal plasma.
Void voluime IR-LPH in plasma of patientts witlh Nelson's syndrome. Three approaches were used to define the natuire of the void volume IR-LPH in the Thze Nature of ImmuntioreactiLve Lipotro pin in Man FIGURE 5 Gel filtration of plasma of two normal subjects drawn under basal fasting conditions. About 600 ml of blood was drawn at 8 a.m., plasma was prepared, and 250 ml were extracted with 100 mg of silicic acid per milliliter of plasma. The extracts were lyophilized, reconstituted in 10 ml of column buffer, and applied to the large Sephadex G-50 column. Conditions were the same as those described in plasma shown in Fig. 2B . With Sephadex G-100 gel filtration, the large IR-LPH still eluted in the void volume, indicating a molecular weight in the globulin range. Next, the ability of silicic acid to extract void volume IR-LPH was examined. Unextracted plasma, the silicic acid extract, and the supernatant plasma left after silicic acid extraction were applied separately to the small Sephadex G-50 column (Fig. 6) . Most of the Silicic acid extract. (C) Supernatant plasma after silicic acid extraction. Conditions and data plotted as in Fig. 1 , except that sample volume was 2.0 ml; fraction volume, 1.6 ml; void volume, 75.2 ml; and total volume, 155.2 ml.
void volume IR-LPH was extracted, but the supernate still contained some void volume IR-LPH (Fig. 6C) . However, none of the IR-LPH extracted by silicic acid eluted in the void volume, most of the ,lLPH was recovered in the extract, and much more yLPH was present in the extract than in the original plasma (Fig.  6A,B) . These data and those from the Gdn-HCl experiment (Fig. 4C) suggested that void volume IR-LPH was yLPH noncovalently bound to a high molectlar weight protein in the patient's plasma. This patient had not been exposed to exogenious natural porcine ACTH (contaminated with BMSH and LPH) for at least 15 yr. However, to explore the possibility that the binding protein was an antibodly, freshly repurified 1251-hyLPH (Dr. Lowry) was added to 0.3 ml of the patient's plasma, diluted to 2.5 ml with RIA standard diluent, and incubated for 48 h at 4°C. Plasma from a patient with Addison's disease (Fig. 2F) served as a control. Total protein-bouind 1251-hyLPH counts were determined by precipitation with polyethylene glycol (22) . Counts bound to immunoglobulins were determined by immunoprecipitation with polyvalent and monospecific antisera to human immunoglobulins. An equal amount of 1251_ hyLPH in the RIA standard diluent served as a precipitation blank. The total proteins in the plasma of the patient with Nelson's syndrome bound 5.2 and 10.0% of the added 125I-hyLPH in two separate experiments; the control patient's plasma with Addison's disease bound only 0.0 and 0.4%. As shown in Fig. 7 , most of the protein-bound 125I-hyLPH was bound to immunoglobulins, mostly to IgG, as were the small number of counts in the plasma of the patient with Addison's disease.
Thus, it appeared that the major binding protein in this patient's plasma was an antibody that reacted both with her own yLPH and with 1251-labeled h'yLPH added to her plasma.
DISCUSSION
The elegant studies of Scott and Lowry (5) first challenged the existence of a 22 amino acid pituitary polypeptide called "human /3MSH" (4). Early studies (21) indicated that the pigmentary factor in human plasma was different from ACTH, but Abe et al. (1), using an aMSH RIA, showed that aMSH accounted for little if any of the biologic MSH activity of human plasma and tissues. However, using an h,3MSH RIA, the same workers concluded that "most of the biologic MSH activity of the plasma and tissues could be accounted for by 18-MSH" (2) and, thus, that "all of the available data support the view that ,B-MSH is the principal melanocyte-stimulating factor in human plasma" (3) . The more recent studies of Scott and Lowry (5) (28) . The present study further suggests that this ectopic tumor peptide may circulate in plasma (Fig. 3D) . These tumors may also contain other melanocyte-stimulating peptides (29) , apparently NH2-terminal 1-13 to 1-15 ACTH f'ragments produced by tutmor endopeptidases from ectopic ACTH (30) .
What, then, of the "h( "big" ACTH is a glycopeptide, presumably the analogue of the 31,000 mol wt common precursor of ACTH and the LPH in the mouse (37) (38) (39) (40) (44) . Thus, the endorphins may be released into the blood in parallel with ACTH and yLPH under physiological situations, such as the response to stress, or under pathological conditions, such as Cushing's disease or the ectopic ACTH syndrome. They may, therefore, account for some of the psychological and physical manifestations of these normal responses and abnormal disease states.
